Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab vs Daratumumab Maintenance in Newly Diagnosed Multiple Myeloma
NCT06931704Phase 2Not yet recruiting
- Sponsor
- CHU de Nantes
- Start
- May 2025
- Primary completion
- Nov 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by CHU de Nantes. Planned start May 2025; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06931704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931704.